Patent · US Active

Fibronectin based scaffold domain proteins that bind to PCSK9

US8420098B2 · kind B2 · utility

77Cited by

18References

8Claims

0Family size

Assignee

Bristol-Myers Squibb Company · US

Inventors

Ray Camphausen · Wayland, US
Jonathan Davis · Waltham, US
Sharon Cload · Cambridge, US
Fabienne M. Denhez · Arlington, US
Amna Saeed-Kothe · Dedham, US
Dasa Lipovsek · Pepperell, US
Ching-Hsiung Frederick Lo · Pennington, US
Chee Meng Low · Singapore, SG
Bowman Miao · Nazareth, US
Tracy S. Mitchell · Andover, US
Rex A. Parker · Titusville, US
Ginger Rakestraw · Cambridge, US
Katie A. Russo · Watertown, US
Doree F. Sitkoff · Dresher, US

Key dates

Filing date	Apr 13, 2011
Grant date	Apr 16, 2013
Priority date	—
Expiry date	Apr 13, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/70
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.